Theriva Biologics Files 8-K
Ticker: TOVX · Form: 8-K · Filed: Oct 8, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, company-update
TL;DR
Theriva Biologics filed an 8-K on Oct 8, 2025, mostly for routine filings.
AI Summary
On October 8, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company was formerly known as Synthetic Biologics, Inc. and is incorporated in Nevada.
Why It Matters
This 8-K filing indicates Theriva Biologics is submitting required documentation to the SEC, potentially related to ongoing operations or financial reporting, though specific material events are not detailed in this excerpt.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing cover page and does not contain information about significant risks or material events.
Key Numbers
- 001-12584 — Commission File Number (SEC filing identifier for Theriva Biologics)
- 13-3808303 — IRS Employer Identification No. (Tax identification for Theriva Biologics)
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former company name
- October 8, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing by Theriva Biologics?
The filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating routine or administrative submissions rather than a specific material event.
When was this 8-K report filed?
The report was filed on October 8, 2025.
What was Theriva Biologics formerly known as?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc.
In which state is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What are the business and mailing addresses listed for Theriva Biologics?
The business and mailing addresses are both listed as 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850.
Filing Stats: 722 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-10-08 08:00:40
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2528131d1_8k.htm (8-K) — 29KB
- tm2528131d1_ex99-1.htm (EX-99.1) — 33KB
- tm2528131d1_ex99-1img001.jpg (GRAPHIC) — 43KB
- tm2528131d1_ex99-1img002.jpg (GRAPHIC) — 15KB
- tm2528131d1_ex99-1img003.jpg (GRAPHIC) — 92KB
- tm2528131d1_ex99-1img004.jpg (GRAPHIC) — 77KB
- tm2528131d1_ex99-1img005.jpg (GRAPHIC) — 71KB
- tm2528131d1_ex99-1img006.jpg (GRAPHIC) — 100KB
- tm2528131d1_ex99-1img007.jpg (GRAPHIC) — 83KB
- tm2528131d1_ex99-1img008.jpg (GRAPHIC) — 92KB
- tm2528131d1_ex99-1img009.jpg (GRAPHIC) — 94KB
- tm2528131d1_ex99-1img010.jpg (GRAPHIC) — 120KB
- tm2528131d1_ex99-1img011.jpg (GRAPHIC) — 67KB
- tm2528131d1_ex99-1img012.jpg (GRAPHIC) — 36KB
- tm2528131d1_ex99-1img013.jpg (GRAPHIC) — 50KB
- tm2528131d1_ex99-1img014.jpg (GRAPHIC) — 84KB
- tm2528131d1_ex99-1img015.jpg (GRAPHIC) — 67KB
- tm2528131d1_ex99-1img016.jpg (GRAPHIC) — 157KB
- tm2528131d1_ex99-1img017.jpg (GRAPHIC) — 105KB
- tm2528131d1_ex99-1img018.jpg (GRAPHIC) — 120KB
- tm2528131d1_ex99-1img019.jpg (GRAPHIC) — 57KB
- tm2528131d1_ex99-1img020.jpg (GRAPHIC) — 90KB
- tm2528131d1_ex99-1img021.jpg (GRAPHIC) — 93KB
- tm2528131d1_ex99-1img022.jpg (GRAPHIC) — 134KB
- tm2528131d1_ex99-1img023.jpg (GRAPHIC) — 45KB
- tm2528131d1_ex99-1img024.jpg (GRAPHIC) — 51KB
- tm2528131d1_ex99-1img025.jpg (GRAPHIC) — 84KB
- tm2528131d1_ex99-1img026.jpg (GRAPHIC) — 85KB
- tm2528131d1_ex99-1img027.jpg (GRAPHIC) — 133KB
- tm2528131d1_ex99-1img028.jpg (GRAPHIC) — 84KB
- tm2528131d1_ex99-1img029.jpg (GRAPHIC) — 98KB
- tm2528131d1_ex99-1img030.jpg (GRAPHIC) — 85KB
- tm2528131d1_ex99-1img031.jpg (GRAPHIC) — 57KB
- tm2528131d1_ex99-1img032.jpg (GRAPHIC) — 55KB
- tm2528131d1_ex99-1img033.jpg (GRAPHIC) — 81KB
- 0001104659-25-097739.txt ( ) — 3825KB
- syn-20251008.xsd (EX-101.SCH) — 3KB
- syn-20251008_lab.xml (EX-101.LAB) — 33KB
- syn-20251008_pre.xml (EX-101.PRE) — 22KB
- tm2528131d1_8k_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Preclinical Data presented at the 32 nd Annual Congress of the European Society of Gene & Cell Therapy 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 8, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer